QTL Effect Interpretation Across Assays And Samples

Why QTL Effects Need Careful Comparison

A molecular QTL estimate is not a scale-free quantity. Its numerical value depends on what was measured, how the phenotype was transformed, which allele defines the effect, and the unit of the predictor. A change of 0.3 in log-base-2 expression and a change of 0.3 in natural-log expression do not represent the same change in abundance. Likewise, a larger estimate from one cohort does not by itself establish a stronger genetic effect: sampling error, measurement precision, and phenotype processing can all differ.

A valid comparison starts by specifying the same target effect in each analysis. For example, the target might be the change in log-base-2 normalized transcript abundance per additional copy of a specified effect allele, conditional on the covariates in the model. Only after checking that the estimates refer to compatible effects should their numerical difference be interpreted as possible heterogeneity.

Definition: A molecular QTL effect estimate, denoted here by \(\hat{\beta}\), is the estimated change in a specified molecular phenotype per unit increase in genotype, under the stated model and conditional on its included covariates. Its interpretation requires the phenotype scale, genotype coding, allele orientation, and measurement context. The standard error \(SE(\hat{\beta})\) quantifies the estimated sampling uncertainty of \(\hat{\beta}\), under the model used to obtain it.

First Align the Effect Scale and Meaning

Suppose a linear QTL model uses genotype dosage \(G\), coded as the number of copies of an effect allele from 0 to 2, and phenotype \(Y\):

E(Y\mid G,C)=\alpha+\beta G+\gamma^{T}C

Here \(C\) represents included covariates. The coefficient \(\beta\) is the expected difference in \(Y\) associated with one additional copy of the effect allele, conditional on those covariates and the model. This interpretation depends on the linear model being an appropriate description of the conditional mean over the observed genotype range. It is not automatically a causal effect.

Before comparing two estimates, check at least the following:

Allele orientation: both estimates must refer to the same allele. If one estimate is coded for the other allele at a biallelic variant, its sign must be reversed.
Genotype unit: confirm that both effects are per allele, rather than, for example, one per allele and one per standard deviation of dosage.
Phenotype definition: check that the assays and processing steps measure sufficiently comparable molecular quantities. The same gene label does not guarantee the same transcript, protein form, or molecular feature.
Phenotype scale: establish whether each estimate is on a raw, logarithmic, standardized, or model-link scale. Equal numerical coefficients on different scales need not mean equal biological changes.
Model context: note the covariates and population analyzed. Even if the target is intended to match, different adjustment choices or sample composition can change the estimated conditional association.

A simple linear change of units can be converted directly. If \(Y^*=aY\) for a fixed positive constant \(a\), then the coefficient and its standard error are both multiplied by \(a\). The same is true of a confidence interval’s endpoints. A nonlinear transformation, however, generally cannot be applied to an estimate and its standard error by simply transforming each in the same way; the uncertainty transformation must be justified. Even a valid scale conversion does not make two different assays measure the same molecular quantity.

Worked Example: Converting a Log-Base-2 Effect

Suppose an assay reports a QTL effect of \(0.300\) log-base-2 expression units per additional effect-allele copy, with \(SE=0.0800\). A second analysis reports natural-log expression. Convert the estimate and standard error to the natural-log scale, and give a 95% confidence interval on that scale.

For a positive abundance value \(A\), \(\log_2(A)=\ln(A)/\ln(2)\). Thus a log-base-2 difference \(\beta_2\) corresponds to a natural-log difference \(\beta_e=\ln(2)\beta_2\). Because this is a constant linear conversion, the standard error is also multiplied by \(\ln(2)\):

\hat{\beta}_e=\ln(2)(0.300)=0.2079,\qquad SE(\hat{\beta}_e)=\ln(2)(0.0800)=0.05545

Using the normal-approximation interval \(\hat{\beta}_2\pm1.96SE(\hat{\beta}_2)\), the unrounded log-base-2 endpoints are \(0.300-1.96(0.0800)=0.1432\) and \(0.300+1.96(0.0800)=0.4568\). Multiplying these endpoints by \(\ln(2)\) gives the natural-log interval:

[0.1432\ln(2),\;0.4568\ln(2)]\approx[0.0993,\;0.3166]

The point estimate corresponds to an abundance ratio of \(2^{0.300}\approx1.231\) per additional effect-allele copy, or about a 23.1% higher abundance on this model’s scale. This is an association interpretation, not evidence that changing the allele would cause that abundance change. The converted coefficient is numerically comparable to an estimate on the natural-log scale only if the phenotype definitions and other aspects of the target effect are also compatible.

Compare Estimates Using Their Uncertainty

When two estimates target the same effect and come from independent samples, their difference can be assessed using the standard error of that difference. Independence here means the estimation errors are independent; disjoint cohorts often support this assumption, though it should not be presumed if samples or controls overlap. Under approximate normality of the estimates, the difference is approximately normal around the difference in the underlying effects.

Result: For independent estimates \(\hat{\beta}_1\) and \(\hat{\beta}_2\), the estimated contrast is \(\hat{\Delta}=\hat{\beta}_1-\hat{\beta}_2\), with \(SE(\hat{\Delta})=\sqrt{SE(\hat{\beta}_1)^2+SE(\hat{\beta}_2)^2}\). A normal-approximation test of equal effects uses \(z=\hat{\Delta}/SE(\hat{\Delta})\). A two-sided \(p\)-value measures how unusual a contrast at least this extreme would be if the underlying effects were equal and the model assumptions held.

The formula follows from the variance of a difference. If the estimation errors are independent, their covariance is zero, so the variance of the difference is the sum of their variances:

\operatorname{Var}(\hat{\beta}_1-\hat{\beta}_2) =\operatorname{Var}(\hat{\beta}_1)+\operatorname{Var}(\hat{\beta}_2) -2\operatorname{Cov}(\hat{\beta}_1,\hat{\beta}_2) =SE(\hat{\beta}_1)^2+SE(\hat{\beta}_2)^2

Worked Example: Comparing Two Independent Cohorts

Two nonoverlapping cohorts analyze the same variant and transcript using the same effect allele, genotype dosage, and log-expression scale. Assume each cohort’s model and covariate adjustment target a comparable conditional association. Cohort 1 estimates \(\hat{\beta}_1=0.240\) with \(SE=0.060\); cohort 2 estimates \(\hat{\beta}_2=0.100\) with \(SE=0.050\). Compare the estimates.

The observed difference is \(0.240-0.100=0.140\) log-expression units per allele. Under the independent-estimates assumption:

SE(\hat{\Delta})=\sqrt{0.060^2+0.050^2} =\sqrt{0.0061}=0.07810

The test statistic is \(z=0.140/0.07810=1.793\), giving a two-sided normal-approximation \(p\)-value of about \(0.073\). The 95% confidence interval for the difference is:

0.140\pm1.96(0.07810)=[-0.0131,\;0.2931]

At a 0.05 significance level, these data do not provide sufficient evidence of a difference between the cohort effects. The interval is also compatible with a modest negative difference or a positive difference as large as about 0.293 log-expression units per allele. This is not proof that the effects are identical. A non-significant difference may reflect limited precision, so the interval and the scientific size of differences it permits matter alongside the \(p\)-value.

Overlapping Samples Require a Covariance Adjustment

If two estimates share donors, their estimation errors may be correlated. In that case, adding the two variances alone gives the wrong standard error for the difference. The general variance formula includes the covariance:

SE(\hat{\beta}_1-\hat{\beta}_2) = \sqrt{SE(\hat{\beta}_1)^2+SE(\hat{\beta}_2)^2 -2\operatorname{Cov}(\hat{\beta}_1,\hat{\beta}_2)}

The covariance can arise, for example, when the same donors contribute measurements to two assays. Its sign and size depend on how the estimates are jointly obtained; overlap does not justify assuming a particular correlation. A paired or joint analysis, or another valid estimate of the covariance, is needed for a defensible contrast. If the covariance is unavailable, report that the uncertainty in the difference cannot be calculated from the two standard errors alone.

Worked Example: Two Assays on the Same Donors

Suppose assays A and B are applied to the same donors, and their effects are on a common, comparable scale with the same allele coding. The estimated effects are \(0.300\) and \(0.220\), with standard errors \(0.060\) and \(0.050\). A joint analysis estimates the correlation between the two effect estimates as \(0.50\). Calculate the uncertainty in their difference.

The estimated covariance is \(0.50(0.060)(0.050)=0.00150\). Therefore:

SE(\hat{\Delta})= \sqrt{0.060^2+0.050^2-2(0.00150)} =\sqrt{0.00310}=0.05568

The difference is \(0.300-0.220=0.080\), so \(z=0.080/0.05568=1.437\), with a two-sided \(p\)-value of about \(0.151\). This does not provide strong evidence of a difference at the 0.05 level. If independence were incorrectly assumed, the standard error would be \(\sqrt{0.060^2+0.050^2}=0.07810\), which is larger in this example because the covariance is positive. The correct calculation depends on the joint sampling structure, not simply on whether the two reported standard errors look similar.

Assessing Variation Across Several Cohorts

With multiple independent estimates on a common scale, Cochran’s \(Q\) summarizes how far they vary around a precision-weighted common estimate. This fixed-effect comparison assumes that each cohort estimates the same underlying effect and that the reported standard errors adequately describe sampling uncertainty. A large \(Q\) relative to its reference distribution is evidence against that common-effect model; it does not identify the reason for disagreement.

Definition: For \(k\) independent estimates \(\hat{\beta}_i\) with standard errors \(SE_i\), set \(w_i=1/SE_i^2\) and calculate the weighted mean \(\hat{\beta}_{w}=\sum_i w_i\hat{\beta}_i/\sum_i w_i\). Cochran’s statistic is \(Q=\sum_i w_i(\hat{\beta}_i-\hat{\beta}_{w})^2\). Under a common-effect model and the stated independence and normal-approximation assumptions, \(Q\) is approximately chi-squared with \(df=k-1\).

Worked Example: Checking Three Cohort Estimates

Three independent cohorts report effects for the same allele and molecular phenotype on a shared log-expression scale. Assume the phenotype and model definitions are comparable, and that the standard errors are valid. The estimates and standard errors are \(0.200\) and \(0.040\), \(0.080\) and \(0.050\), and \(0.240\) and \(0.060\). Calculate the weighted mean and \(Q\).

The weights are \(625\), \(400\), and \(277.78\). The weighted mean is:

\hat{\beta}_{w} =\frac{625(0.200)+400(0.080)+277.78(0.240)} {625+400+277.78} =\frac{223.67}{1302.78}=0.1717

Using the unrounded weighted mean, the contributions to \(Q\) are approximately \(0.501\), \(3.362\), and \(1.296\). Thus \(Q\approx5.160\), with \(df=3-1=2\). The upper-tail probability for a chi-squared distribution with 2 degrees of freedom is approximately \(0.0757\). At the 0.05 level, this is not sufficient evidence to reject the common-effect model.

A descriptive measure often reported with \(Q\) is \(I^2=\max\{0,(Q-df)/Q\}\times100\%\). Here it is approximately \((5.160-2)/5.160\times100\%=61.2\%\). This indicates that the observed dispersion is substantial relative to the amount expected from sampling error under the common-effect model, but with only three cohorts the heterogeneity assessment is uncertain. The non-significant \(Q\) test does not establish homogeneity, and \(I^2\) does not explain why the estimates differ.

Interpreting Differences Across Assays

Cohort heterogeneity and assay differences are related but not interchangeable. Cohorts may differ in ancestry, environmental context, cell composition, or technical processing; assays may differ in sensitivity, dynamic range, and the molecular feature they quantify. These differences can affect both standard errors and the effect being estimated. A statistically detectable contrast between assays could therefore reflect a genuine difference in measured molecular response, a mismatch in phenotype definition, or technical distortion. Conversely, similar estimates do not prove that assays have identical measurement properties.

Standardized effects require particular care. Dividing an effect by the phenotype’s standard deviation expresses it in standard-deviation units, but the standard deviation can differ across cohorts or assays. Consequently, equal standardized effects need not imply equal changes in the original molecular units, and equal unstandardized effects need not imply equal standardized effects. State which scale is being compared rather than treating either as universally preferable.

A useful report makes the comparison auditable: name the variant and effect allele, the molecular feature and assay, the phenotype transformation and units, the cohort, the estimate and standard error, and whether sample overlap was handled. Present a contrast and uncertainty when testing a difference. For several cohorts, state the heterogeneity statistic, degrees of freedom, and its limitations. Avoid treating a difference in significance labels as a test of a difference in effects: one estimate can be significant and another not, even when their underlying effects are compatible.

Common Pitfall

Wrong reasoning: “Assay A has a significant QTL and assay B does not, so the genetic effect must be assay-specific.”
Correction: Significance depends on both effect size and precision. Compare the estimates directly on a compatible scale, calculate the uncertainty of their difference using the appropriate covariance, and interpret the contrast in light of the measurement definitions. A difference in significance alone is not evidence that the effects differ.

Key takeaway: A QTL effect comparison is meaningful only after the allele, genotype unit, phenotype, and scale have been aligned. Then use the uncertainty of the contrast—not separate significance labels—to assess differences, and interpret any remaining heterogeneity in light of assay and cohort context.

Check Your Understanding

Try these questions before moving on.

A coefficient is reported per additional copy of one allele in one cohort and per copy of the alternate allele in another. What adjustment is needed before comparing the signs and values?
If a phenotype is multiplied by a positive constant, what happens to its QTL coefficient, standard error, and confidence-interval endpoints?
Two independent cohorts have estimates \(0.12\) and \(0.20\), with standard errors \(0.03\) and \(0.04\). What formula gives the standard error of their difference?
Why can the independent-estimates formula be inappropriate when the same donors contribute to two assays?
What does a non-significant Cochran’s \(Q\) test establish, and what does it not establish?